Clinical trials

Essentials of Clinical Research

Volumn , Issue , 2008, Pages 29-62

  Glasser, Stephen P ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891457983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8486-7_3     Document Type: Chapter

References (54)

1. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Jama. Jul 3 2002;288(1):49-57
2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Jama. Aug 19 1998;280(7):605-613
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. Jama. Jul 17 2002;288(3):321-333
4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. Dec 15 1992;117(12):1016-1037
5. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med. Jan 1991;20(1):47-63
6. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med. Dec 1990;150(12):2557-2562
7. Glasser SP, Howard G. Clinical trial design issues: At least 10 things you should look for in clinical trials. J Clin Pharmacol. Oct 2006;46(10):1106-1115
8. Grimes DA, Schulz KF. An overview of clinical research: The lay of the land. Lancet. Jan 5 2002;359(9300):57-61
9. Loscalzo J. Clinical trials in cardiovascular medicine in an era of marginal benefit, bias, and hyperbole. Circulation. Nov 15 2005;112(20):3026- 3029
10. Bienenfeld L, Frishman W, Glasser SP. The placebo effect in cardiovascular disease. Am Heart J. Dec 1996;132(6):1207-1221
11. Clark PI, Leaverton PE. Scientific and ethical issues in the use of placebo controls in clinical trials. Annu Rev Public Health. 1994;15:19-38
12. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. N Engl J Med. Aug 11 1994;331(6):394-398
13. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: A systematic review. Jama. Nov 2 2005;294(17):2203-2209
14. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ. 1948;ii:769-782
15. Reviews of statistical and economic books, Student's Collected Papers. J Royal Staitistical Society. 1943;106:278-279
16. A Village of 100 A Step Ahead
17. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med. Aug 15 1991;325(7):445-453
18. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Jama. May 10 1995;273(18):1421-1428
19. Lang JM. The use of a run-in to enhance compliance. Stat Med. Jan-Feb 1990;9(1-2):87-93; discussion 93-85
20. Shem S. The House of God: Palgrace Macmillan; 1978:280
21. Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. Prospective, randomized, openlabel, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebocontrolled trials with respect to ABPM measurements. J Hypertens. Jul 2003;21(7):1291-1298
22. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. Jama. Sep 24 1982;248(12):1465-1477
23. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. Apr 14 1994;330(15):1029-1035
24. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. Bmj. Sep 11 1999;319(7211):670-674
25. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. Oct 30 1980;303(18):1038-1041
26. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. The Anturane Reinfarction Trial Research Group. N Engl J Med. Jan 31 1980;302(5):250-256
27. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med. Dec 27 1979;301(26):1410-1412
28. Howard G, Chambless LE, Kronmal RA. Assessing differences in clinical trials comparing surgical vs nonsurgical therapy: Using common (statistical) sense. Jama. Nov 5 1997;278(17):1432-1436
29. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. Mar 25 2000;355(9209):1064-1069
30. Sleight P. Debate: Subgroup analyses in clinical trials: Fun to look at -but don't believe them! Curr Control Trials Cardiovasc med. 2000;1(1):25-27
31. Amarenco P, Goldstein LB, Szarek M, et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. Dec 2007;38(12): 3198-3204
32. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. Jama. Apr 23-30 2003;289(16):2073-2082
33. Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenkofske S. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. Sep 2005;46(3):508-513
34. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of non-inferiority: The ximelagatran experience. J Am Coll Cardiol. Dec 6 2005;46(11):1986-1995
35. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. Jama. Mar 8 2006;295(10):1147-1151
36. Fleming TR, DeMets DL. Surrogate end points in clinical trials: Are we being misled? Ann Intern Med. Oct 1 1996;125(7):605-613
37. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med. Apr 1989;8(4):431-440
38. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll Cardiol. May 1 2002;39(9):1414-1421
39. Kelsen DP. Surrogate endpoints in assessment of new drugs in colorectal cancer. Lancet. Jul 29 2000;356(9227):353-354
40. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A metaanalysis. Meta-Analysis Group in Cancer. Lancet. Jul 29 2000;356(9227):373-378
41. Greene HL, Roden DM, Katz RJ, Woosley RL, Salerno DM, Henthorn RW. The Cardiac Arrhythmia Suppression Trial: First CAST . then CAST-II. J Am Coll Cardiol. Apr 1992;19(5):894-898
42. FDA Adviser Questions Surrogate Endpoints for Diabetes Drug Approvals. Medpage Today; 2007
43. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: A basis for a rational approach. Eur J Clin Pharmacol. 1992;43(3):235-244
44. Montori VM, Busse JW, Permanyer-Miralda G, Ferreira I, Guyatt GH. How should clinicians interpret results reflecting the effect of an intervention on composite endpoints: Should I dump this lump? ACP J Club. Nov-Dec 2005;143(3): A8
45. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: Greater precision but with greater uncertainty? Jama. May 21 2003;289(19):2554-2559
46. Lauer MS, Topol EJ. Clinical trials-multiple treatments, multiple end points, and multiple lessons. Jama. May 21 2003;289(19):2575-2577
47. Kip K, Hollabaugh K, Marroquin O, Williams D. The problem with composite endpoinmts in cardiovascular studies. J Am Coll Cardiol. 2008;51:701-707
48. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS) : A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. Mar 21 2000;101(11):1297-1302
49. Bokhari F, Newman D, Greene M, Korley V, Mangat I, Dorian P. Long-Term comparison of the implantable cardioverter defibrillator versus amiodarone: Eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS). Circulation. Jul 13 2004;110(2):112-116
50. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. Jama. Apr 4 2001;285(13):1711-1718
51. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama. Dec 18 2002;288(23):2981-2997
52. Starzl TE, Donner A, Eliasziw M, et al. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet. Nov 18 1995;346(8986):1346-1350
53. Ioannidis JPA. Why most published research findings are false. PLoS. 2005;2:0696-0701
54. Toma M, McAlister FA, Bialy L, Adams D, Vandermeer B, Armstrong PW. Transition from meeting abstract to full-length journal article for randomized controlled trials. Jama. Mar 15 2006;295(11):1281-1287